GMA-105 is under clinical development by Gmax Biopharm and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GMA-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GMA-105 overview

GMA-105 is under development for the treatment of obesity. The drug candidate is a humanized anti-GLP-1R monoclonal antibody carrying a GLP-1 fragment. It is administered through subcutaneous route.

Gmax Biopharm overview

Gmax Biopharm is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. The company is headquartered in Hangzhou, China.

For a complete picture of GMA-105’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.